Managers / Q1 2020 · view latest →
Versant Venture Management, LLC
CIK 0001560009 · ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO, CA, 94104 · 650-233-7877
Summary
Versant Venture Management, LLC reported $364.6B in U.S.-listed holdings across 9 positions for Q1 2020.
The portfolio is heavily concentrated: Crispr Therapeutics alone accounts for 48.6% of reported value.
Compared with Q4 2019, the fund opened 2 new positions and exited 0.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 51.2% · $186.9B
- Other · 48.8% · $177.8B
Quarter-over-Quarter Changes full breakdown →
vs Q4 2019 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| ADVMCHFAdverum Biotechnologies, Inc. | NEW | +7.07M | 7.07M | +$69.1B | $69.1B |
| AKROAkero Therapeutics, Inc. | NEW | +2.74M | 2.74M | +$58.0B | $58.0B |
| Second Sight Medical Products, Inc. | TRIMMED | −3.93M | 561.6K | −$2.8B | $559M |
| CRISPR Therapeutics AG | HELD | +0 | 4.21M | −$78.9B | $177.2B |
| 2JQGritstone Oncology, Inc. | HELD | +0 | 3.10M | −$9.8B | $18.1B |
| VCYTVeracyte, Inc. | HELD | +0 | 1.21M | −$4.4B | $29.3B |
| OCULOcular Therapeutix, Inc. | HELD | +0 | 2.22M | +$2.2B | $11.0B |
| CLVSEURClovis Oncology, Inc. | HELD | +0 | 101.9K | −$414M | $648M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2020
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | CRISPR Therapeutics AG | Common Stock | 48.60% | $177.2B | 4.21M |
| 2 | ADVMCHFAdverum Biotechnologies, Inc.history → | Common Stock | 18.94% | $69.1B | 7.07M |
| 3 | AKROAkero Therapeutics, Inc.history → | Common Stock | 15.91% | $58.0B | 2.74M |
| 4 | VCYTVeracyte, Inc.history → | Common Stock | 8.04% | $29.3B | 1.21M |
| 5 | 2JQGritstone Oncology, Inc.history → | Common Stock | 4.95% | $18.1B | 3.10M |
| 6 | OCULOcular Therapeutix, Inc.history → | Common Stock | 3.01% | $11.0B | 2.22M |
| 7 | CymaBay Therapeutics, Inc. | Common Stock | 0.22% | $805M | 543.8K |
| 8 | CLVSEURClovis Oncology, Inc.history → | Common Stock | 0.18% | $648M | 101.9K |
| 9 | Second Sight Medical Products, Inc. | Common Stock | 0.15% | $559M | 561.6K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $141M | 8 | May 5, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $151M | 7 | Feb 12, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $212M | 9 | Nov 10, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $82M | 8 | Aug 11, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $60M | 7 | May 7, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $87M | 7 | Feb 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $64M | 6 | Nov 8, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $77M | 8 | Aug 7, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $103M | 7 | May 3, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $389M | 7 | Feb 8, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $188M | 8 | Nov 3, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $84M | 8 | Aug 9, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $48M | 7 | May 11, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $48M | 7 | Feb 9, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $59M | 8 | Nov 10, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $65M | 8 | Aug 11, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $100M | 10 | May 10, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $187M | 10 | Feb 11, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $242M | 11 | Nov 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $302M | 11 | Aug 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $513M | 11 | May 7, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $963M | 12 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | Under review | 11 | Nov 12, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $696.1B | 12 | Jul 20, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $364.6B | 9 | Apr 28, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $331.8B | 7 | Jan 21, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $258.5B | 8 | Oct 8, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $343.2B | 9 | Jul 12, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $303.6B | 9 | Apr 5, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $202.0B | 10 | Jan 22, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.